Novartis AG (NVS) shares have seen diverse investment decisions as several investment firms buy or sell their stocks in the pharmaceutical giant. For instance,
Jackson Square Capital LLC, Dynamic Advisor Solutions LLC, Sivia Capital Partners LLC, and others bought shares, while others like
Acadian Asset Management LLC, Arvest Investments Inc. offloaded theirs. The ongoing acquisition of
Regulus Therapeutics and the signing of a
$5.7 billion licensing deal with Monte Rosa have stoked overall sentiment. Additionally, the
$1.4 billion deal that Novartis recently signed raised a few eyebrows while other stakeholders label it as a move that 'Makes Sense.'
In contrast, despite the active pipeline progress and strong Q2 performance that has initiated a stock buyback of $10 billion, Goldman Sachs has reiterated a 'Sell' rating for NVS citing growth concerns. The rating is based on the contention that the stock is considered overvalued, resulting in a dip of 4.6% mainly due to growth concerns. Despite this, Novartis remains a top value stock for the long term.
Novartis Stocks News Analytics from Tue, 29 Apr 2025 07:00:00 GMT to Sun, 21 Sep 2025 01:54:13 GMT -
Rating 4
- Innovation 5
- Information 6
- Rumor -3
